Lee S - Search Results

1

A Paradoxical Effect of Interleukin-32 Isoforms on Cancer.

Shim S, Lee S, Hisham Y, Kim S, Nguyen TT, Taitt AS, Hwang J, Jhun H, Park HY, Lee Y, Yeom SC, Kim SY, Kim YG, Kim S. Shim S, et al. Among authors: lee y, lee s. Front Immunol. 2022 Feb 25;13:837590. doi: 10.3389/fimmu.2022.837590. eCollection 2022. Front Immunol. 2022. PMID: 35281008 Free PMC article. Review.

2

Comparison of the Seven Interleukin-32 Isoforms' Biological Activities: IL-32θ Possesses the Most Dominant Biological Activity.

Shim S, Lee S, Hisham Y, Kim S, Nguyen TT, Taitt AS, Hwang J, Jhun H, Park HY, Lee Y, Yeom SC, Kim SY, Kim YG, Kim S. Shim S, et al. Among authors: lee y, lee s. Front Immunol. 2022 Feb 25;13:837588. doi: 10.3389/fimmu.2022.837588. eCollection 2022. Front Immunol. 2022. PMID: 35281066 Free PMC article.

3

Cloning and characterization of bovine interleukin-32 beta isoform.

Jaekal J, Jhun H, Hong J, Park S, Lee J, Yoon D, Lee S, Her E, Yang Y, Rho G, Kim S. Jaekal J, et al. Among authors: lee j, lee s. Vet Immunol Immunopathol. 2010 Sep 15;137(1-2):166-71. doi: 10.1016/j.vetimm.2010.04.019. Epub 2010 May 7. Vet Immunol Immunopathol. 2010. PMID: 20537728

4

Identification of constitutively active interleukin 33 (IL-33) splice variant.

Hong J, Bae S, Jhun H, Lee S, Choi J, Kang T, Kwak A, Hong K, Kim E, Jo S, Kim S. Hong J, et al. Among authors: lee s. J Biol Chem. 2011 Jun 3;286(22):20078-86. doi: 10.1074/jbc.M111.219089. Epub 2011 Mar 22. J Biol Chem. 2011. PMID: 21454686 Free PMC article.

5

IL-32γ overexpression accelerates streptozotocin (STZ)-induced type 1 diabetes.

Jhun H, Choi J, Hong J, Lee S, Kwak A, Kim E, Jo S, Ryoo S, Lim Y, Yoon DY, Hong JT, Kim TS, Lee Y, Song K, Kim S. Jhun H, et al. Among authors: lee y, lee s. Cytokine. 2014 Sep;69(1):1-5. doi: 10.1016/j.cyto.2014.05.002. Epub 2014 May 22. Cytokine. 2014. PMID: 25022955

6

Structural Characteristics of Seven IL-32 Variants.

Sohn DH, Nguyen TT, Kim S, Shim S, Lee S, Lee Y, Jhun H, Azam T, Kim J, Kim S. Sohn DH, et al. Among authors: lee y, lee s. Immune Netw. 2019 Apr 16;19(2):e8. doi: 10.4110/in.2019.19.e8. eCollection 2019 Apr. Immune Netw. 2019. PMID: 31089435 Free PMC article. Review.

7

Interleukin-32 gamma specific monoclonal antibody and developing IL-32 specific ELISA.

Lee S, Kim S, Bae S, Choi J, Hong J, Ryoo S, Jhun H, Hong K, Kim E, Jo S, Her E, Kim S. Lee S, et al. Hybridoma (Larchmt). 2010 Dec;29(6):501-9. doi: 10.1089/hyb.2010.0059. Epub 2010 Nov 18. Hybridoma (Larchmt). 2010. PMID: 21087097

8

Contradictory functions (activation/termination) of neutrophil proteinase 3 enzyme (PR3) in interleukin-33 biological activity.

Bae S, Kang T, Hong J, Lee S, Choi J, Jhun H, Kwak A, Hong K, Kim E, Jo S, Kim S. Bae S, et al. Among authors: lee s. J Biol Chem. 2012 Mar 9;287(11):8205-13. doi: 10.1074/jbc.M111.295055. Epub 2012 Jan 23. J Biol Chem. 2012. PMID: 22270365 Free PMC article.

9

Characterizing antiviral mechanism of interleukin-32 and a circulating soluble isoform in viral infection.

Bae S, Kang D, Hong J, Chung B, Choi J, Jhun H, Hong K, Kim E, Jo S, Lee S, Kim SH, Kim S. Bae S, et al. Among authors: lee s. Cytokine. 2012 Apr;58(1):79-86. doi: 10.1016/j.cyto.2011.12.024. Epub 2012 Jan 25. Cytokine. 2012. PMID: 22277801

10

The inhibitory function of Fc-ST2 depends on cell type; IL-1RAcP and ST2 are necessary but insufficient for IL-33 activity.

Hong K, Lee Y, Lee S, Hong S, Bae S, Hong J, Choi J, Jhun H, Kwak A, Kim E, Jo S, Kang T, Cho YS, Kim YG, Kim S. Hong K, et al. Among authors: lee y, lee s. Immunol Res. 2013 May;56(1):122-30. doi: 10.1007/s12026-013-8388-9. Immunol Res. 2013. PMID: 23435764

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

127,472 results

Search Page